NZ716426B2 - Binding polypeptides having a mutated scaffold - Google Patents

Abstract

The present disclosure relates to a class of engineered polypeptides and provides a polypeptide comprising the sequence EX2X3X4AX6X7EIX10 X11 LPNLX16X17X18QX20 X21AFIX25X26LX28X29X30 PX32QSX35X36LLX39E AKKX45X46X47Q. The present disclosure also relates to populations of polypeptide variants based on a common scaffold, each polypeptide in the population comprising the amino acid sequence EX2X3X4AX6X7EIX10 X11 LPNLX16X17X18QX20 X21AFIX25X26LX28X29X30 PX32QSX35X36LLX39E AKKLX45X46X47Q, and methods for selecting a desired polypeptide having an affinity for a predetermined target from said population. a common scaffold, each polypeptide in the population comprising the amino acid sequence EX2X3X4AX6X7EIX10 X11 LPNLX16X17X18QX20 X21AFIX25X26LX28X29X30 PX32QSX35X36LLX39E AKKLX45X46X47Q, and methods for selecting a desired polypeptide having an affinity for a predetermined target from said population.

Description

BINDING POLYPEPTIDES HAVING A D SCAFFOLD Field of the ion The present invention relates to novel polypeptides, s of production thereof and novel populations of polypeptide variants based on a common scaffold. The populations can for example be used to provide novel binding proteins and polypeptides.

Background Different s for construction of novel binding proteins have been described (Nygren PA and Uhlén M (1997) Curr Opin Struct Biol 7:463-469).

One strategy has been to combine library generation and screening with selection for desired properties.

First generation Z variant ptides based on a common, first generation scaffold, populations of such molecules and methods involving them have been described in WO95/19374. onally, Z variant polypeptides based on a second generation scaffold, populations of such molecules and s involving them have been described in WO2009/080811. The teachings of these two disclosures are incorporated herein by reference.

For some applications, Z variant polypeptides or populations f having ed properties, such as higher alkali stability, low antigenicity, structural stability, amenability to chemical synthesis and hydrophilicity, are desired. WO2009/080811 discloses Z variants having a common scaffold with improved ties, but not every desired property can be obtained by Z variant polypeptides as described therein.

One of the key factors to success for polypeptide pharmaceuticals is their stability. Polypeptides showing a high structural stability will most likely functionally withstand chemical modifications, changes in physical conditions and proteolysis, both during production as well as within the human body.

Moreover, stability will influence the active shelf-life of polypeptide 2014/068259 pharmaceuticals, as well as the active life of the polypeptide pharmaceutical within the human body.

Hence, there is a continued need for improving the stability of Z variant polypeptides.

Description of the invention It is an object of the present invention to provide a polypeptide with a novel scaffold, which polypeptide alleviates the above—mentioned and other cks of currently available 2 variant polypeptides.

Another object of the present invention is to e a method for production of a polypeptide based on a novel scaffold.

It is also an object of the present invention to provide a population of such improved polypeptide variants, all based on a novel ld.

Another object of the present invention is to provide a population of polynucleotides.

Yet r object of the present invention is to provide a combination of a ptide tion and a cleotide population.

A further object of the present invention is to provide a method for selecting a desired polypeptide having an affinity for a predetermined target from a population of polypeptides.

Another object is to provide a method for isolating a polynucleotide encoding a desired polypeptide having an affinity for a predetermined target.

Another object is to provide a method for identifying a desired polypeptide having an affinity for a predetermined target.

A further object is to provide a method for selecting and identifying a desired polypeptide having an affinity for a ermined target.

A related object is to provide a method for production of a desired polypeptide having an affinity for a predetermined target.

These and other objects may be achieved by different s disclosed in the present application.

In a first aspect of the present sure, there is provided a polypeptide comprising an amino acid sequence selected from i) EX2X3X4AX5X7E|X10 X11LPNLX15X17X1gQX20 X21AF|X25X25LX25X29X30 PX3zQSX35X35LLX39E AKKLX45X45X47Q, wherein eaCh 0f X2, X3. X4, X6, X7, X10, X11, X17, X18, X20, X21, X25 and X28 independently corresponds to any amino acid e; and wherein, independently of each other, X15 is selected from N and T; X25 is selected from K and S; X29X50PX32 is selected from DDPS and RQPE; X55 is selected from A and S; X35 is selected from E and N; X39 is selected from A, C and S; X45 is selected from E, N and S; X45 is selected from D, E and 8, provided that X45 is not D when X45 is N; X47 is selected from A and S; and an amino acid sequence which has at least 91 % identity to the ce defined in i), provided that X45 is not D when X45 is N.

Within the polypeptide sequence i) above, each amino acid X defined as endently corresponding to any amino acid” individually corresponds to an amino acid e which is selected from all possible amino acids. For clarity, this applies to amino acid positions corresponding to the positions X2, X3, X4, X6, X7, X10, X11, X17, X18, X20, X21, X25 and X28 in sequence I) above.

This means that each such X may be any amino acid residue, independent of the identity of any other residue denoted X in the sequence. In the amino acid sequence, these amino acids X may be chosen from all 20 naturally occurring amino acid residues in such a way that any of these 20 lly occurring amino acid residues may be present at the corresponding X position in any given variant. The selection of amino acid residue in each position may be more or less randomized. It is also possible to limit the group from which the different varied amino acid residues are selected to 19, 18, 17, 16 or less of the 20 naturally occurring amino acid residues. The variability in different positions may be adjusted individually, between one, meaning no randomization, up to all 20 amino acids. Random introduction of a r subset of amino acids may be ed by careful selection of the deoxyribonucleotide bases introduced, for example the codons T(A/C)C may be introduced to obtain a random introduction of either serine or tyrosine at a given position in the polypeptide chain. Likewise, the codons (T/C/A/G)CC may be introduced to obtain a random introduction of phenylalanine, leucine, alanine and valine at a given position in the polypeptide chain. The skilled person is aware of many alternatives of deoxyribonucleotide base combinations that may be used to obtain different ations of amino acids at a given position in the polypeptide chain. The set of amino acids that may appear at a given position in the polypeptide chain may also be ined by the introduction of leotides during the oligonucleotide synthesis, instead of one deoxyribonucleotide base at a time. A defined set of amino acids may also be obtained using split-pool sis enabling incorporation of defined codons in desirable positions in the synthesis. Yet another alternative to obtain randomized double stranded s is by incorporation of randomized sets of trinucleotide ng blocks using ligations and restrictions of the subsequently built up double stranded DNA.

In one embodiment of the present disclosure, there is provided a polypeptide having affinity for a predetermined target. In one such ment, the amino acid residues that confer target binding specificity are those in the positions corresponding to ons 2, 3, 4, 6, 7, 10, 11, 17, 18, 20, 21, 25 and 28 in sequence i) above. Likewise, in such a polypeptide, amino acid residues that do not confer target binding specificity are referred to as “scaffold amino acids” or simply “scaffold”. Accordingly, in one embodiment, scaffold amino acid residues as defined herein are those in the positions ponding to positions 1, 5, 8, 9, 12-15, 19, 22—24, 27, 31, 33- 34, 37-38, 40—44 and 48 in ce i) above. The skilled person will appreciate that the advantageous properties conferred by the scaffold amino acids of the polypeptides as defined herein are independent of the target binding icity of said polypeptide.

As the skilled person will e, the function of any polypeptide, such as the polypeptide of the present disclosure, is dependent on the tertiary structure of the polypeptide. It is therefore possible to make minor changes to the sequence of amino acids in a polypeptide without affecting the function thereof. Thus, the disclosure encompasses modified variants of said polypeptide that do not alter the onal properties of the ptide, such as its improved stability and/or its binding affinity for a predetermined target.

In this way, also encompassed by the present disclosure is a polypeptide comprising an amino acid sequence with 91 % or greater identity to a sequence defined in i). In some embodiments, the polypeptide may comprise a sequence which is at least 93 %, such as at least 95 %, such as at least 97 % cal to the sequence defined in i).

In some embodiments, such differences between sequence definitions i) and ii) may be found in any position of the sequence of the polypeptide as disclosed herein. In other embodiments, such changes may be found only in scaffold amino acid residues. In other embodiments, said changes may be found only in the amino acid es which confer target binding specificity.

For example, it is possible that an amino acid residue belonging to a certain functional grouping of amino acid residues (e.g. hydrophobic, hydrophilic, polar etc) could be exchanged for another amino acid residue from the same functional group.

The term "% ty", as used throughout the specification, may for example be calculated as s. The query sequence is aligned to the target sequence using the CLUSTAL W algorithm son et al, Nucleic Acids Research, 22: 4673—4680 (1994)). A comparison is made over the window corresponding to one of the aligned sequences, for example the shortest. The window may in some instances be defined by the target sequence. In other instances, the window may be defined by the query sequence. The amino acid residues at each position are compared, and the percentage of positions in the query sequence that have cal correspondences in the target sequence is reported as % identity.

When used as scaffolds for binding ptides, the sequences disclosed herein provide advantages compared to known, similar scaffolds, and have been engineered to show a high structural stability and hence an improved storage shelf-life. These advantages also apply to the third aspect of the disclosure (see further below), which relates to populations of the polypeptide variants of this first aspect.

In one embodiment of the t disclosure, X16 is T.

In one embodiment, X25 is K.

In one embodiment, X29X30PX32 is DDPS.

In one embodiment, X29X30PX32 is RQPE.

In one ment, X35 is S.

In one embodiment, X36 is E.

In one ment, X39 is S.

In one embodiment, X45 is selected from E and S.

In one embodiment, X45 is E.

In one ment, X45 is S.

In one embodiment, X45 is selected from E and S.

In one ment, X45 is E.

In one embodiment, X46 is S.

In one embodiment, X45 is D.

In one embodiment, X45 is not D or E when X45 is N.

In one embodiment, X45X46 is selected from EE, ES, SE and 88, such as from ES and SE.

In one embodiment, X45X45 is ES.

WO 28550 In one embodiment, X45X45 is SE.

In one ment, X45X45 is SD.

In one embodiment, X47 is S.

The term ”binding affinity for a predetermined ” as used in this specification refer to a property of a polypeptide which may be tested for example by the use of surface plasmon resonance (SPR) technology. For example, said binding affinity may be tested in an experiment in which the predetermined target, or a fragment thereof, is immobilized on a sensor chip of the instrument, and the sample containing the ptide to be tested is passed over the chip. Alternatively, the polypeptide to be tested is immobilized on a sensor chip of the instrument, and a sample containing the predetermined target, or a nt thereof, is passed over the chip. The skilled person may then interpret the results obtained by such experiments to establish at least a qualitative measure of the binding affinity of the ptide for the ermined target. If a quantitative measure is desired, for example to determine a KD value for the interaction, surface plasmon resonance methods may also be used. g values may for example be defined in a Biacore (GE Healthcare) or ProteOn XPR 36 (Bio-Rad) instrument. The predetermined target is suitably immobilized on a sensor chip of the instrument, and samples of the polypeptide whose affinity is to be determined are prepared by serial dilution and injected in random order. KD values may then be calculated from the results using for example the 1:1 Langmuir binding model of the BIAevaluation 4.1 software, or other suitable software, provided by the instrument manufacturer.

The term ”binding affinity for a predetermined ”, as used herein, may also refer to a ty of a polypeptide which may be tested for example by ELISA. For example, the binding affinity may be tested in an experiment in which samples of the polypeptide are captured on dy-coated ELISA plates and biotinylated predetermined , or a nt thereof, is added, followed by streptavidin conjugated HRP. TMB substrate is added and the absorbance at 450 nm is measured using a multi-well plate reader, such as Victor3 (Perkin Elmer). The skilled person may then interpret the results obtained by such experiments to establish at least a qualitative measure of the binding affinity of the complex for the predetermined target. If a quantitative e is desired, for example to determine the E050 value (the half maximal effective concentration) for the interaction, ELISA may also be used. The response of the ptide against a dilution series of the predetermined target, or a fragment thereof, is measured using ELISA as described above. The skilled person may then interpret the s obtained by such experiments, and E050 values may be calculated from the results using for example ad Prism 5 and non—linear regression.

As previously described, Z variant polypeptides are believed to constitute, or form part of, a three—helix bundle protein domain, the motif having ty for a predetermined target ially forming part of two alpha helices with an onnecting loop, within said three-helix bundle protein domain.

Different modifications of, and/or additions to, the polypeptide as defined above may be performed in order to tailor the polypeptide to the specific use intended, without ing from the scope of the present invenflon.

Such modifications and additions are described in more detail below, and may comprise additional amino acids comprised in the same polypeptide chain, or labels and/or therapeutic agents that are chemically conjugated or otherwise bound to the polypeptide.

Hence, in one embodiment, there is provided a polypeptide as described above comprising additional amino acid es. In some embodiments additional amino acid residues may be located at the C- terminus of the polypeptide. In some embodiments additional amino acid residues may be located at the N-terminus of the polypeptide.

In one embodiment, said additional amino acid residues at the C- terminus comprise AP.

In one embodiment, said additional amino acid residues at the N- us comprise AEAKYAK.

In yet another embodiment, there is ed a polypeptide as described above, which consists of sequence i) or ii) having from 0 to 7 additional amino acid residues at the N—terminus and from 0 to 3 onal amino acid residues at the C-terminus.

WO 28550 The additional amino acid residues may play a role in the binding of the polypeptide, but may equally well serve other purposes, related for example to one or more of the production, purification, stabilization, coupling or detection of the polypeptide. In some embodiments, said additional amino acid residues constitute one or more polypeptide (s).

Such additional amino acid residues may comprise one or more amino acid residues added for purposes of chemical ng. An example of this is the addition of a cysteine residue at the very first or very last position in the polypeptide chain, i.e. at the N- or C-terminus. A cysteine residue to be used for chemical ng may also be introduced by replacement of r amino acid on the surface of the protein , preferably on a portion of the surface that is not involved in target binding. Such additional amino acid residues may also comprise a “tag” for purification or detection of the polypeptide, such as a hexahistidyl (Hiss) tag, or a “myc” tag or a “FLAG” tag for interaction with antibodies specific to the tag. The d person is aware of other alternatives.

The “additional amino acid residues” discussed above may also constitute one or more polypeptide domain(s) with any desired function, such as another binding function, or a half-life extending function, or an enzymatic function, or a metal ion chelating function, or a fluorescent function, or any combination thereof.

In one example embodiment, there is provided a compound having affinity for a predetermined target, said compound sing: A. at least one polypeptide as d above; B. at least one albumin binding domain of streptococcal protein G, or a derivative thereof; and C. optionally, at least one linking moiety for linking said at least one n binding domain or derivative thereof to the C or N terminus of said at least one polypeptide. miting examples of tives of the albumin binding domain of streptococcal protein G are disclosed in W02009/016043 and W02012/004384.

Also, in a further embodiment, there is provided a polypeptide as defined above, which ses an amino acid sequence ed from: YAK EX2X3X4AX5X7EIX10 X11LPNLX15X17X18QX20 X21AF|X25X25LX28X29X30 PX32QSX35X36LLX39E AKKLX45X46X47Q AP; and FNK EX2X3X4AX5X7E|X10 X11LPNLX15X17X1sQX2O X21AF|X25X25LX28X29X30 PngQSX35X36LLX39E AKKLX45X46X47Q AP. wherein each Xy is defined as above (and y denotes the amino acid position of residue X within the polypeptide sequence defined by i) above).

In some embodiments, there is ed a ptide, which comprises an amino acid sequence selected from ADNNFNK EX2X3X4AX6X7E|X10 X1 1 LP N LX15X17X18QX20 X21AF |X25X25LX28X29X30 PstQSX35X35LLX39E AKKLX45X45X47Q AP K; ADNKFNK EX2X3X4AX5X7E|X10 X11LPNLX16X17X18QX20 X21AF|X25X25LX28X29X30 PX3zQSX35X35LLX39E AKKLX45X45X47Q APK; VDNKFNK EX2X3X4AX6X7EIX10 X11LPNLX15X17X1gQX20 X25X25LX28X29X30 PngQSX35X35LLX39E AKKLX45X45X47Q APK; VDAKYAK EX2X3X4AX6X7E|X10 X11LPNLX16X17X1BQX20 X21AFIX25X26LX28X29X30 PX3zQSX35X36LLX39E AKKLX45X45X47Q APK; and AEAKYAK 4AX6X7EIX10 X11LPNLX16X17X1gQX20 X21AF|X25X26LX28X29X30 PXazQSX35X35LLX39E AKKLX45X45X47Q APK; wherein Xy is defined as described above (and y denotes the amino acid on of residue X within the polypeptide sequence defined by i) above).

The polypeptide variants disclosed herein may be generated by taking a Z variant polypeptide, for example based on a known scaffold and having affinity for a given target, and performing site-directed mutagenesis at ed positions to obtain a polypeptide having a scaffold according to the t disclosure, retaining the target affinity. A polypeptide according to the present disclosure may, alternatively, be made by chemical synthesis of the entire molecule or by using other molecular biology s, known to a person skilled in the art, to graft the binding motif of a Z variant polypeptide onto the scaffold sed herein.

As a general illustration, original Z variant polypeptides comprising the ing common scaffold sequence and having a binding specificity defined by the amino acid sequence within a binding motif [BM]: AEAKYAK-[BM]-DDPSQSSELL SEAKKLNDSQ APK may be modified to provide a polypeptide as disclosed herein.

In various specific embodiments of this aspect of the sure, the following polypeptides are ed: AEAKYAK-[BM]-RQPEQSSELL SEAKKLNDSQ APK AEAKYAK-[BM]—DDPSQSSELL SEAKKLSESQ APK AEAKYAK-[BM]—DDPSQSSELL SEAKKLESSQ APK AEAKYAK-[BM]—DDPSQSSELL SEAKKLSDSQ APK AEAKYAK-[BM]—DDPSQSSELL SEAKKLNESQ APK AEAKYAK-[BM]—RQPEQSSELL SEAKKLSESQ APK AEAKYAK-[BM]-RQPEQSSELL SEAKKLESSQ APK AEAKYAK-[BM]-RQPEQSSELL SEAKKLSDSQ APK AEAKYAK-[BM]—RQPEQSSELL SEAKKLNSSQ APK The polypeptides disclosed herein have many applications, for e applications of therapeutic, diagnostic or prognostic significance for a disease. A non-limiting list of diseases, in which said polypeptides may find therapeutic, diagnostic or prognostic use, es , inflammatory diseases, autoimmune e, infectious diseases, neurological diseases, neurodegenerative diseases, eye diseases, kidney diseases, pulmonary es, diseases of the gastrointestinal tract, cardiovascular diseases, hematological diseases, dermatological diseases, allergies and other.

Thus, in one embodiment, there is ed a polypeptide with affinity for a predetermined target. In more specific embodiments, said target is selected from the group consisting of HER2, TNFd, EGFR, IGF1 R, lgG, PDGFRB, HER3, C5, FcRn, CAIX, amyloid [5, CD4, IL8, |L6 and insulin. In other embodiments, said ptide may be of use in biotechnological, industrial and pharmaceutical applications, for e use as an affinity ligand in separation technology, purification applications or as a detection agent. In a more specific such embodiment, the predetermined target may be an albumin binding domain (“ABD” or “GA module”) from streptococcal Protein G, or a derivative thereof.

The skilled person will appreciate that the list of predetermined targets is to be viewed as non—limiting, and that polypeptides as defined herein with affinity for other predetermined targets fall within the scope of the present disclosure.

Non-limiting examples of known Z t ptides, based on a known scaffold and having affinity for different targets, are Z variants with ty for the EGF receptor (disclosed in WO2007/065635), for the HER2 receptor osed in WO2009/O80810), for the HER3 receptor (disclosed in WO2010/056124), for the IGF1 receptor (disclosed in W02009/019117), for the PDGF receptor [5 (disclosed in WO2009/077175), for the albumin binding domain (ABD) (disclosed in W02014/064237), for the neonatal Fc or (FcRn) (disclosed in ) and for carbonic anhydrase IX (disclosed in WO2014/096163). Note, for clarity, that in the present disclosure, a Z variant’s binding motif [BM] corresponds to the first 28 amino acid residues of those binding motifs disclosed in the documents listed above, in which the definitions of g motifs are 29 amino acid residues and correspond to the amino acid residues at positions corresponding to positions 1-29 of ce i) above. in one embodiment, there is provided a polypeptide with an affinity for a predetermined target, which further comprises a label, such as a label selected from the group consisting of scent dyes and , chromophoric dyes, chemiluminescent compounds and bioluminescent proteins, enzymes, radionuclides and particles. Such labels may for example be used for detection of the polypeptide.

In some embodiments, the polypeptide is present as a moiety in a fusion polypeptide or conjugate also comprising a second moiety having a desired biological activity. Non-limiting examples of such a desired biological activity comprise a eutic activity, a binding ty, and an enzymatic activity.

In some embodiments, said moiety further comprises a label. The label may in some instances be coupled only to the polypeptide with ty for a ermined target, and in some instances both to the polypeptide with affinity for a predetermined target and to the second moiety of the conjugate or fusion polypeptide. Furthermore, it is also possible that the label may be coupled to a second moiety only and not to the polypeptide with affinity for a predetermined target. Hence, in yet another embodiment there is provided a polypeptide with affinity for a predetermined target comprising a second moiety, wherein said label is coupled to the second moiety only.

Herein disclosed polypeptides orfusion polypeptides may be used as detection reagents, capture reagents, as separation reagents, as diagnostic agents for diagnostics in vivo or in vitro, or as therapeutic agents. s that employ the ptides or fusion polypeptides ing to the present disclosure in vitro may be performed in different formats, such as in microtiter plates, in n arrays, on biosensor es, on tissue ns, and so on.

It should also be understood that the polypeptide or fusion polypeptides according to the present disclosure may be useful as a therapeutic, diagnostic or prognostic agent in its own right or as a means for targeting other therapeutic, diagnostic or prognostic agents, with e.g. direct or indirect effects on said target. A direct therapeutic effect may for example be accomplished by inhibiting signaling by said . Said target may also serve as a valuable marker to predict the sis of certain es (for example the diseases listed above).

Hence, in one embodiment there is provided a polypeptide or fusion polypeptide as described herein for use in therapy or for use as a diagnostic agent. In another embodiment, said polypeptide or fusion polypeptide further comprises a therapeutic agent. Non-limiting examples of such therapeutic agents are a therapeutic agent potentiating the effect of said ptide or fusion polypeptide, a therapeutic agent acting in synergy with said polypeptide or fusion polypeptide and a therapeutic agent affecting a ent aspect of the disease to be treated. Also envisioned are pharmaceutical compositions comprising polypeptides as disclosed herein, alone or together with r therapeutic agents.

In a second aspect of the present disclosure, there is provided a polynucleotide encoding a polypeptide or a fusion polypeptide as described herein. Also encompassed by this disclosure is a method of producing a polypeptide or fusion polypeptide as described above comprising expressing such a polynucleotide; an expression vector comprising the polynucleotide; and a host cell comprising said expression vector.

In a third aspect of the present disclosure, there is provided a population of ptide variants based on a common scaffold, each polypeptide in the tion comprising an amino acid sequence selected from: i) EX2X3X4AX5X7EIX10 X11LPNLX15X17X1gQX20 X21AF|X25X25LX28X29X30 X35X35LLX39E AKKLX45X45X47Q, wherein eaCh 0f X2, X3, X4, X6, X7, X10, X11, X17, X18, X20, X21, X25 and X28 independently corresponds to any amino acid residue; and wherein, ndently of each other, X15 is selected from N and T; X25 is selected from K and S; X29X30PX32 is selected from DDPS and RQPE; X35 is selected from A and S; X35 is selected from E and N; X39 is selected from A, C and S; X45 is selected from E, N and S; X46 is selected from D, E and 8, provided that X45 is not D when X45 is N; X47 is selected from A and S; and ii) an amino acid sequence which has at least 91 % identity to the sequence defined in i), provided that X46 is not D when X45 is N.

In sequence i) above, each of X2, X3, X4, X6, X7, X10, X11, X17, X18, X20, X21, X25 and X28 individually corresponds to an amino acid residue which is varied in the population. Hence, each such amino acid residue may be any amino acid residue independent of the identity of any other residue denoted Xy in the sequence, as ned above in tion with the first (polypeptide) aspect of the disclosure. Non-limiting s for specific amino acid residues Xy in the population of polypeptides, and for any additional amino acid residues at either terminal of sequence i) or ii), are the same as those listed above as embodiments of the first aspect of the sure.

As discussed above, polypeptides comprising minor changes as compared to the above amino acid sequences without largely affecting the 2014/068259 tertiary structure and the function thereof are also within the scope of the present disclosure. Thus, also encompassed by the present disclosure is a population of polypeptide variants based on a common scaffold, wherein each polypeptide in the population comprises an amino acid sequence with 91 % or greater identity to a sequence as defined in i). In some embodiments, each polypeptide may comprise a sequence which is at least 93 %, such as at least 95 %, such as at least 97 % cal to the sequence as defined in i).

The tion defined herein consists of a large number of unique and different variants of the defined polypeptide molecules. In this context, a large number may for example mean that the population comprises at least 1 X 104 unique polypeptide molecules, or at least 1 x 106, at least 1 x 108, at least 1 x 1010, at least 1 x 1012, or at least 1 x1014 unique polypeptide molecules. As the skilled person will appreciate, it is necessary to use a group that is large enough to provide the desired size of the population. The “population” described herein may also be denoted “library”.

The d person will appreciate that the population as disclosed herein may be useful as a library for selection of new binding molecules based on the polypeptide defined in i). It is well known in the art that binding les may be isolated from a population (or library) of randomized polypeptides. This technology is described in l terms in PCT publication WO95/19374, in Nord et al (1997) Nature Biotechnology 15:772- 777 and in W02009/080811, and has been successfully applied in order to select binding molecules based on a common 2 domain scaffold against a variety of target molecules through the random variation of thirteen different target binding positions and subsequent selection of s of interest in a phage display or other selection system based on genotype—phenotype coupling. The population as sed herein is a tion of polypeptide variants which exhibit improved properties, in particular in terms of stability, compared to populations in the prior art. Examples of Z ts ed from a population (or library) of randomized polypeptides include Z variants with affinity for the EGF receptor (disclosed in W02007/065635), for the HER2 receptor (disclosed in W02009/080810), for the HER3 receptor (disclosed in WO2010/056124), for the IGF1 receptor (disclosed in WO2009/019117), for the PDGF receptor B (disclosed in /077175), for ABD osed in WO2014/064237), for the neonatal Fc receptor (FcRn) (disclosed in ) and for carbonic anhydrase IX (disclosed in W02014/096163).

In a fourth aspect of the t disclosure, there is provided a population of polynucleotides. Each cleotide in this population encodes a member of a population of polypeptides as defined above in connection with the third aspect.

In a fifth aspect of the t sure, there is provided a combination of a ptide population ing to the third aspect and a polynucleotide population according to the , in which combination each member of the polypeptide population is physically or spatially associated with a corresponding polynucleotide encoding that member via means for genotype-phenotype coupling. This physical or spatial association will be more or less strict, depending on the system used.

The means for genotype-phenotype coupling may comprise a phage display system. Phage y systems are well-known to the skilled person, and are, for example, described in Smith GP (1985) Science 228:1315-1317 and Barbas CF et a/ (1991) Proc Natl Acad Sci U S A 88:7978—7982.

Furthermore, the means for genotype-phenotype coupling may comprise a cell surface display system. The cell surface display system may comprise prokaryotic cells, such as ositive cells, or eukaryotic cells, such as yeast cells. Cell surface display systems are well-known to the skilled person. Prokaryotic systems are, for example, described in Francisco JA et al (1993) Proc Natl Acad Sci U S A 90:10444-10448 and Lee SY et al (2003) Trends Biotechnol 21 :45-52. Eukaryotic systems are, for example, described in Boder ET et al (1997) Nat Biotechnol 15:553-557 and Gai SA et al (2007) Curr Opin Struct Biol -473. In one embodiment, said genotype- ype coupling may comprise a phage display system.

Furthermore, the means for genotype-phenotype coupling may comprise a cell free display system. The cell free display system may comprise a me display system, or an in vitro compartmentalization display , or a system for 0/3 display, or a microbead display system.

Ribosome display systems are well-known to the skilled person, and are, for example, described in Mattheakis LC of a/ (1994) Proc Natl Acad Sci U S A 91 9026 and Zahnd C et al (2007) Nat Methods 4269279. In vitro compartmentalization systems are well—known to the skilled person, and are, for example, described in Sepp A et al (2002) FEBS Lett 532:455-458. Cis display systems are well-known to the skilled person, and are, for example, described in Odegrip R et a/ (2004) Proc Natl Acad Sci U S A 101 2810.

Microbead display systems are well-known to the skilled person, and are, for example, described in Nord 0 eta/ (2003) J Biotechnol 13.

Furthermore, the means for genotype-phenotype coupling may comprise a non-display system such as the protein-fragment complementation assay (PCA). PCA systems are well-known to the d person, and are, for example, described in Koch H eta/ (2006) J Mol Biol 357:427-441 .

In a sixth aspect of the t disclosure, there is provided a method for selecting a desired polypeptide having an affinity for a predetermined target from a population of polypeptides, comprising the steps: (a) providing a tion of polypeptides ing to the third aspect; (b) bringing the population of polypeptides into contact with the predetermined target under conditions that enable specific interaction between the target and at least one desired polypeptide having an affinity for the target; and (c) selecting, on the basis of said specific interaction, the at least one desired polypeptide from the remaining population of polypeptides.

Below, this method is called the “selection method” according to the sure.

Step (a) may se the preparatory steps of ing a population of polynucleotides and expressing said population of polynucleotides to yield said population of polypeptides. The means for yielding a population of polypeptides varies depending on the display system used and examples of such means may be found in the genotype-phenotype references above.

Each member of said population of polypeptides used in the selection method may ally be associated with the polynucleotide encoding that member via means for genotype-phenotype coupling. The means for genotype— phenotype coupling may be one of those discussed above.

Step (b) comprises the steps of bringing the tion of polypeptides into contact with the predetermined target under conditions that enable specific interaction between the target and at least one desired polypeptide having an affinity for the target. The range of conditions applicable is determined by the robustness of the , the robustness of the display system, and by the desired properties of the interaction with the target. For example a specific method of separating the interaction such as acidification to a predetermined pH may be desired. The skilled person knows what experiments are required to determine suitable ions.

Step (0) comprises the selection of at least one polypeptide. The means for ion of desired polypeptide from the ing population, based on the specific interaction between the predetermined target and at least one desired polypeptide having affinity for the target varies depending on the display system used and may be found in the genotype-phenotype nces above. For e, the in vitro display selection systems are cell free in contrast to systems such as phage display and the protein fragment compartmentalization assay.

In an seventh aspect of the present disclosure, there is provided a method for isolating a polynucleotide encoding a desired polypeptide having an affinity for a predetermined target, comprising the steps: - selecting said desired polypeptide and the polynucleotide encoding it from a population of polypeptides using the selection method according to the sixth aspect; and - isolating the thus separated polynucleotide ng the desired polypeptide.

Below, this method is called the “isolation method” according to the disclosure.

The separation of the cleotide from the polypeptide may be done differently depending on the display system used for selection. For example, in the cell free display systems such as cis display and ribosome display the cleotide or the corresponding mRNA is ved through efficient elution from the polypeptide using means described in the genotype- phenotype references above.

The isolation of the polynucleotide may be done by ent methods depending on the display system used for selection. In most of the above described selection systems, for example the protein fragment complementation assay, the cleotide can be directly isolated by specific PCR amplification using appropriate oligonucleotides. Also, as in ribosome display, the polynucleotide can be isolated from the corresponding mRNA using reverse transcription. The s means for isolation of the polynucleotide may be found in the genotype-phenotype references above.

In an eighth aspect of the present disclosure, there is provided a method for identifying a desired polypeptide having an affinity for a predetermined target, comprising the steps: - isolating a polynucleotide ng said d polypeptide using the isolation method according to the seventh ; and - sequencing the cleotide to establish by deduction the amino acid sequence of said desired polypeptide.

The sequencing of the polynucleotide may be done according to standard procedures well-known to the skilled person.

In a ninth aspect of the present disclosure, there is provided a method for selecting and identifying a desired polypeptide having an affinity for a predetermined target from a tion of polypeptides, comprising the steps: (a) synthesizing each member of a population of polypeptides according to the third aspect on a te carrier or bead; (b) selecting or enriching the carriers or beads based on the interaction of the polypeptide with the predetermined target; and (c) identifying the polypeptide by protein characterization methodology.

In step (c), it is for example possible to use mass spectrometric analysis.

Below, this method is called the “selection and fication method” ing to the disclosure.

In a tenth aspect of the t disclosure, there is provided a method for production of a desired polypeptide having an affinity for a predetermined target, comprising the steps: - ing and identifying a desired polypeptide using the selection method according to the sixth aspect or the selection and identification method according to the ninth aspect; and — producing said desired polypeptide.

Below, this method is called the ction method” according to the sure.

In the production method, production may be carried out using recombinant expression of a polynucleotide encoding the d polypeptide.

The production may also be carried out using chemical synthesis of the desired polypeptide de novo.

In an th aspect of the present disclosure there is provided a method for production of a desired polypeptide having an affinity for a predetermined target, comprising the steps: (a1) isolating a polynucleotide encoding said desired polypeptide using the isolation method according to the seventh aspect; or (a2) backtranslating a polypeptide identified using the selection and identification method according to the ninth aspect; and (b) sing the thus isolated polynucleotide to produce said desired polypeptide, wherein step (b) is performed either after step (a1) or step (a2).

The polypeptides, tions and methods according to the disclosure enable the ion of agents with an affinity for a predetermined target, h the provision of a polypeptide that is characterized by specific binding to the predetermined .

It is also possible to provide polypeptides binding to a ermined target that exhibit little or no non—specific binding.

It is also possible to provide polypeptides g to a ermined target that can readily be used as a moiety in a fusion polypeptide.

Furthermore, it is possible to provide polypeptides binding to a predetermined target that solve one or more of the known ms experienced with existing antibody reagents.

Moreover, it is possible to provide polypeptides binding to a predetermined target that are amenable to use in therapeutic and/or diagnostic applications.

It is also possible to provide polypeptides binding to a predetermined target that are easily made by chemical peptide synthesis.

Furthermore, the invention enables the identification of ptides binding to a predetermined target that exhibit an improved stability vis-a-vis known agents binding to the same target.

It is also le to provide polypeptides binding to a predetermined target that exhibit low antigenicity when used in vivo in a mammal and/or that exhibit an improved biodistribution upon administration to a mammal.

The modifications discussed above for the polypeptides constituting the population according to the present disclosure are also applicable to the polypeptides obtained by any of the above mentioned methods.

Polypeptides according to the present disclosure may be produced by any known means, ing chemical synthesis or expression in different prokaryotic or eukaryotic hosts, including bacterial cells, yeast cells, plant cells, insect cells, whole plants and transgenic animals.

While the ptides, populations of polypeptides and methods for fication, selection, isolation and production disclosed herein have been described with reference to various exemplary aspects and embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In addition, many modifications may be made to adapt a particular situation or molecule to the ngs of the invention without departing from the essential scope thereof. Therefore, it is intended that the sure not be limited to any particular embodiment contemplated, but to include all embodiments g within the scope of the appended claims.

Brief description of the figures Figure 1 is a listing of the amino acid sequences of examples of a polypeptide as disclosed herein. Sequences of C5 binding Z variant polypeptides shown in Examples 2—3 to have improved stability are listed in Figure 1 as SEQ ID NO:12, 17, 18 and 22, and the sequences thereof corresponding to the shortest sequence defined herein are listed as SEQ ID NO:19-21. The amino acid sequences of C5 binding ptides fused to albumin binding domains are in Figure 1 with ce identifiers SEQ ID NO:4-11, 13-16 and 23-25. Sequences of Z variant ptides with affinity for HER2, B, FcRn and CAIX shown in Example 12 to have ed stability are listed as SEQ ID NO:28—29, SEQ ID NO:31-32, SEQ ID NO:34-35 and SEQ ID 42, respectively, together with the corresponding control polypeptides SEQ ID NO:27, 30, 33 and 36. The sequences of said Z variant polypeptides with affinity for HER2, B, FcRn and CAIX corresponding to the shortest sequence defined herein are listed as SEQ ID NO:43-54.

Additionally, the amino acid sequences of a control C5 binding polypeptide, the control C5 binding polypeptide fused to albumin, the n g domain and of human C5 are listed as SEQ ID NO:26, 1, 2 and 3, respectively.

Figure 2 is an image of a SDS-PAGE gel wherein the first lane ns SeeBlue 2P size marker and the bands represent the C5 binding polypeptide PSI0242 (SEQ ID NO:1) (0) prior to stability test; and (2w) after a 2 week stability test.

Figure 3 is a togram from reversed phase HPLC of 2 (SEQ ID NO:1) prior to stability test (solid line) and after a 2 week stability test (dotted line).

Figure 4 is an image of a SDS-PAGE gel wherein the first lane contains SeeBlue 2P size marker and the bands represent (0) the l samples; and (2w) the samples after a 2 week stability test. A: SEQ ID NO:1; B: SEQ ID NO:13; C: SEQ ID NO:14; D: SEQ ID NO:16.

Figure 5 is a chromatogram from reversed phase HPLC of a modified C5 inhibitor (SEQ ID NO:5) prior to stability test (solid line) and after a 2 week stability test (dotted line).

Figure 6 is a chromatogram from reversed phase HPLC of a modified C5 inhibitor (SEQ ID NO:16) prior to stability test (solid line) and after a 2 week stability test (dotted line).

Figure 7 are CD spectra collected for A: 217351 (SEQ ID NO:37); B: 217352 (SEQ ID NO:38); C: 217355 (SEQ ID NO:39); D: 217357 (SEQ ID NO:40); E: 217359 (SEQ ID NO:41); F: 217360 (SEQ ID NO:42); and G: 209782 (SEQ ID NO:36).

Figure 8 are images of SDS-PAGE gels showing original and inventive polypeptides before (0) and after a 2 week (2w) stability test. A: Polypeptides targeting HER2: lane 1: Mw, lane 2: 202891 (0), lane 3:202891 (2w), lane 4: Mw, lane 5: 217341 (0), lane 6: 217341 (2w), lane 7: 217342 (0), lane 8: 217342 (2w); B: Polypeptides targeting B: lane 1: Mw, lane 2: 215805 (0), lane 3:215805 (2w), lane 4: Mw, lane 5: 217343 (0), lane 6: 217343 (2w), lane 7: 217344 (0), lane 8: 217344 (2w); C: Polypeptides targeting FcRn: lane 1: 210103 (0), lane 2:210103 (2w), lane 3: Mw, lane 4: 217347 (0), lane 5: 217347 (2w), lane 6: 217348 (0), lane 7: 217348 (2w); and D: Polypeptides targeting CAIX: lane 1:Mw, lane 2: 209782 (0), lane 3:209782 (2w), lane 4: Mw, lane 5: 217351 (0), lane 6: 217351 (2w), lane 7: 217352 (0), lane 8: 217352 (2w); lane 9: 217355 (0), lane 10: 217355 (2w), lane 11: 217357 (0), lane 12: 217357 (2w), lane 13: 217359 (0), lane 14: 217359 (2w), lane 15: 217360 (0), lane 16: 217360 (2w). The molecular size marker (Mw) was Novex® Sharp ained Protein Standard (216, 160, 110, 80, 60, 50, 40, 30, 20, 15, 10, 3.5 kDa). (The diagonal bands seen in Figure 8C are an artifact resulting from an imprint from a second gel stained in the same container).

Figure 9 shows sensorgrams of binding of 2 variants comprising the amino acid tutions ND to SE in position 52-53 (black) and original 2 variants (gray) with affinity for the same target after a 2 week stability test. A: Binding of 2017341 (SEQ ID N028) and 202891 (SEQ ID NO:27) to HER2; B: Binding of 2017343 (SEQ ID NO:31) and 215805 (SEQ ID NO:30) to B; C: Binding of 2017347 (SEQ ID NO:34) and 210130 (SEQ ID NO:33) to FcRn and D: Binding of 2017351 (SEQ ID NO:37) and 209782 (SEQ ID NO:36) to CAIX. The injected concentrations of each 2 variant were as bed in Example 13.

Examples The following Examples disclose novel 2 variant polypeptides exhibiting improved stability. Herein, the properties of 2 variant polypeptides based on previous generations of scaffolds were compared with 2 variant polypeptides based on the scaffold disclosed herein.

Comparative example 1 Stability test of known C5 binding 2 variant A C5 g 2 t designated PSI0242 (SEQ ID NO:1) was formulated in 25 mM NaP I125 mM NaCI pH 7.0 and subjected to an accelerated stability study for 2 weeks at 37°C. The stability was measured by the appearance of new variants after the stability testing by SDS—PAGE and Reversed Phase HPLC (RPC). In both analyses, the initial sample and the one subjected to the ity study were run in parallel. For the SDS—PAGE, 7.5 ug protein was loaded into each well. The RPC was run on an Agilent 1100 HPLC using a Mobile Phase A consisting of 0.1% trifluoroacetic acid (TFA) in water, and a Mobile Phase B consisting of 0.1% TFA / 45 % MeOH / 45 % isopropylamine (lPA)/ 10 % water.

The results show that new forms of the protein were formed during tion, visualized as bands in SDS—PAGE (Fig. 2) and as new peaks in Reversed Phase HPLC (RPC) chromatograms (Fig. 3). In Fig. 3, the main peak after incubation for 2 weeks corresponds to 57 % of the original protein sample.

Positions 1-60 in SEQ ID NO:1 pond to the polypeptide 206175a, previously disclosed in WO2013/126006 as SEQ ID NO:753.

Example 2 Stability test of modified C5 binding polypeptides and nds Modified C5 binding polypeptides and compounds were synthesized and purified essentially as described in WO2013/126006.

Briefly, DNA encoding C5 binding Z variants were E. coli codon optimized and synthesized by GeneArt, GmbH. The synthetic genes representing the new C5 binding Z variants were subcloned and expressed in E. coli. lntracellularly expressed Z variants were ed using tional tography methods. Homogenization and clarification was performed by sonication followed by centrifugation and filtration. Anion exchange chromatography was used as capture step. Further purification was obtained by hydrophobic interaction chromatography. The purifications were executed at acidic conditions (pH 5.5). Polishing and buffer exchange was performed by size exclusion chromatography.

The purified proteins were formulated in 25 mM NaP l125 mM NaCl pH 7.0 and ted to an accelerated stability study for 2 weeks at 37 °C. The stability was measured by the appearance of new variants after the stability g by SDS—PAGE and Reversed Phase HPLC (RPC). In both analyses, the initial sample and the one subjected to the stability study were run in parallel. For the SDS—PAGE, 7.5 pg protein was loaded into each well. An example of a resulting gel is shown in Fig. 4.

The RPC was run on an Agilent 1100 HPLC using a Mobile Phase A consisting of 0.1 % trifluoroacetic acid (TFA) in water, and a Mobile Phase B consisting of0.1 % TFA / 45 % MeOH /45 % pylamine (lPA)/ 10 % water. An example of a resulting chromatogram for SEQ ID NO:5 is shown in Fig. 5.

The s of the stability testing are summarized in Table 1.

SDS—PAGE RPC Main peak (% of RPC SEQ ID NO' . . _ Desngnation bands prepeaks total protein) postpeaks 1 PSI0242 2 2 57 1 4 PSI0332 2 1 57 1 PSI0334 1 1 73 0 6 PSI0335 2 2 57 1 7 PSI0336 2 2 57 1 8 7 2 2 57 1 9 PSI0339 2 2 57 1 1O PSI0340 2 2 67 1 11 PSI0369 2 1 90 1 12 PSI0377 1 0 77 0 13 PSI0378 1 0 89 0 14 PSI0379 1 0 88 0 PSI0381 1 0 87 0 16 PSI0383 1 0 91 0 22 PSI0400 1 0 91 0 23 PSIO410 1 1 72 1 24 PSI0403 1 1 77 1 4 1 1 88 0 Table 1. Stability of Z variant polypeptides after 2 weeks of incubation at 37 °C. Results from SDS-PAGE and HPLC are compared.

WO 28550 It can be concluded from Table 1 that certain modified C5 binding polypeptides or compounds have improved properties, such as increased stability, when compared with PSI0242. Such improved C5 binding ptides or compounds include 4 (SEQ ID NO:5), 0 (SEQ ID NO:10), PSI0369 (SEQ ID NO:11), PSI0377 (SEQ ID NO:12), PSI0378 (SEQ ID NO:13), PSI0379 (SEQ ID NO:14), PSI0381 (SEQ ID NO:15), PSI0383 (SEQ ID NO:16), PSI0400 (SEQ ID NO:22), PSI0410 (SEQ ID NO:23), PSI0403 (SEQ ID N024) and 4 (SEQ ID NO:25). Six of the mentioned variants (SEQ ID NO:5, 12, 13, 14, 16 and 22) have in common that the amino acid residues in positions 52-53 have been substituted from ND (cf. 2) to SE. In SEQ ID NO:15, the corresponding substitution is from ND to ES. In SEQ ID NO:24 only the amino acid residue in position 53 has been tuted from D to E, while in SEQ ID NO:25 the amino acid residue in position 52 has been substituted from N to S.

Example 3 Binding of modified compounds to human C5 Human serum albumin was immobilized to Amine Reactive 2nd generation (ARZG) Dip and Read Biosensors (Pall Life sciences (ForteBio) Cat # 18-5092) by amine coupling. PSI0242 (SEQ ID NO:1; 1 (M) and modified C5 binding compounds (1 uM) in read buffer (HBS-EP Buffer [10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005 % Surfactant P20], GE Healthcare, cat. no. BR100188) were loaded, each onto a separate sensor with HSA, for 120 seconds followed by a base line recording for 60 seconds in read buffer before being subjected to human C5 (Quidel, cat. no.

A403) at concentrations ranging from 0.79 nM to 25 nM in read buffer with a regeneration cycle and a base line recording between each tration.

Regeneration ions for the sensors were 10 mM Glycine, pH 2 (three pulses with 30 seconds and running buffer for 60 seconds). Each spectrogram was reference subtracted against that of an analogous construct containing an albumin binding domain (SEQ ID NO:2) but without the C5 binding capacity. The data were analyzed according to Langmuir 1:1 model using ForteBio Analysis 7.1 (Pall Life sciences (ForteBio) cs re).

The relative KD of the interaction of PSI0242 (SEQ ID NO;1) with C5 is shown in Table 2. The KB of PSI0242 (SEQ ID NO:1) varied from 1—3 nM in different runs.

The s in Table 2 indicate that C5 binding compounds according to the present disclosure have a binding capacity to human C5 which is similar to that of the polypeptide PSI0242 (SEQ ID NO:1) disclosed in WO2013/126006.

SEQ ID NO: Designation Rel. KB 1 2 1.0 PSI0334 1.1 13 PSI0378 1.3 PSI0381 23 16 PSI0383 2.1 Table 2. Kg value of the interaction of SEQ ID NO:5, 13, 15 and 16 with 05 compared to KD value of C5 interaction with SEQ ID NO:1 Example 4 Stability of chemically synthesized C5 binding polypeptide A chemically sized 0 (SEQ ID NO:22) was ordered from BACHEM AG. The stability of the polypeptide was tested according to the same methodology as in Example 2. The results of the stability testing are shown in Table 3.

SEQ ID Designation SDS-PAGE RPC Main peak RPC NO bands prepeaks (% of total protein) aks 22 PSI0400 1 0 91 0 Table 3. Stability of the chemically ed CS binding polypeptide PSI0400 (SEQ ID NO:22) after 2 weeks of incubation WO 28550 The stability of PSI0400 was comparable to the same polypeptide produced in E.coii in Example 2.

The integrity of the fold of PSI0400 (SEQ ID NO:22) was compared to a recombinant C5 binding polypeptide (PSI0257, SEQ ID NO:26), produced in accordance with the methods of Example 2, using far UV circular dichroism (CD) spectra.

The CD spectra were recorded by a J-720 CD spectropolarimeter (Jasco, Japan). The samples were diluted to 0.17 mg/ml protein concentration using Pi buffer (5 mM Na—K-PO4, pH 7.0). A CD spectrum of Pi buffer was firstly recorded, then a were recorded for each of the samples and lastly for the Pi buffer again. As the two buffer spectra coincide, the firstly recorded spectrum was used as the buffer spectrum. The buffer spectrum was smoothened using the Savitzky-Golay procedure with convolution width of 25.

The other spectra were smoothened according to the same procedure with a convolution width of 15. The smoothened buffer spectrum was then subtracted from each of the other ened spectra. The CDNN program was used to estimate the secondary content of the proteins and the ing tions are presented in Table 4. The results showed that neither the two amino acid substitutions at position 52 and 53 nor the polypeptide production by chemical synthesis influence the secondary structure content of the chemically synthesized polypeptide. The integrity of the secondary structure t was compared to the recombinantly produced PSI0257 (SEQ ID \ SEQ ID NO:26 SEQ ID NO:22 Helix l 63 % 69 % Antiparallel i 3 % 2 % Parallel l 3 % 3 % urn l 13 % 12 % Rndm. Coil 11 % Table 4. Comparison of secondary structure content for two 05 g polypeptides as determined by CD Example 5 Binding of modified 2 ts and polypeptides to human C5 The binding affinity of the C5 binding compounds PSI0242 (SEQ ID NO:1), PSI0340 (SEQ ID NO:10) 8 (SEQ ID NO:13), and PSI041O (SEQ ID N023) and the C5 binding polypeptide PSI0400 (SEQ ID NO:22) for human C5 was analyzed using a Biacore T200 instrument (GE Healthcare).

Human C5 (Quidel, cat. no. A403) was coupled to a CM5 sensor chip (900 RU) using amine coupling chemistry according to the manufacturer’s protocol.

The coupling was performed by injecting hC5 at a concentration of 7.5 ug/ml in 10 mM tate buffer pH 5 (GE care). The reference cell was treated with the same reagents but t injecting human C5. Binding of the C5 polypeptide and compounds to immobilized hC5 was studied with the single cycle kinetics method, in which five concentrations of sample, typically , 12.5, 6.25, 3.12 and 1.56 nM in HBS-EP buffer were injected one after the other at a flow rate of 30 ullmin at 25 °C in the same cycle without regeneration n injections. Data from the reference cell were subtracted to compensate for bulk refractive index changes. In most cases, an injection of HBS-EP was also included as control so that the sensorgrams were double blanked. The es were regenerated in HBS-EP buffer. Kinetic constants were calculated from the sensorgrams using the Langmuir 1:1 analyte model of the Biacore T200 Evaluation re version 1.0. The resulting KD values of the interactions are presented in Table 5.

SEQ ID NO: Designation KD (nM) 1 PSI0242 1.3 PSI0340 2.5 13 8 2.1 22 PSI0400 0.53 23 PSIO410 1.3 Table 5. Kg value of the interaction of SEQ ID NO:10, 13, 22 and 23 with 05 compared to KD value of C5 interaction with SEQ ID NO:1 The present data show that the stability-enhancing amino acid substitutions do not have any significant negative effect on the ability of the molecules to bind to C5, and thus do not influence their biological activities. tion of hemolysis For studies of cal complement pathway on and inhibition thereof by the C5 binding compounds PSI0378 (SEQ ID NO:13) and PSI0410 (SEQ ID N023), and C5 binding polypeptide PSI0400 (SEQ ID NO:22), sheep erythrocytes were prepared from fresh sheep whole blood in Alsever's solution (Swedish National Veterinary Institute). The erythrocytes were thereafter treated with rabbit anti-sheep erythrocyte antiserum (Sigma) to become dy sensitized sheep erythrocytes (EA). The whole process was ted under aseptic conditions. All other reagents were from commercial The in vitro assay was run in 96-well U-form microtiter plate by consecutive additions of a test protein, a complement serum and EA suspension. The final concentrations of all reagents, in a total reaction volume of 50 ul per well and at pH 7.3-7.4, were: 0.15 mM CaCl 2; 0.5 mM MgCl 2; 3 mM NaN 3; 138 mM NaCl; 0.1 % gelatin; 1.8 mM sodium barbital; 3.1 mM barbituric acid; 5 million EA; complement protein C5 serum at suitable dilution, and C5 binding nd or ptide at desired concentrations.

The C5 binding compounds and polypeptide were pre—incubated with the above described complement serum for 20 min on ice prior to starting the reaction by the addition of EA suspension. The hemolytic reaction was allowed to proceed at 37 °C under conditions of agitation for 45 min and was then optionally ended by addition of 100 pl ice-cold saline containing 0.02 % Tween 20. The cells were centrifuged to the bottom of the vial and the upper portion, corresponding to 100 pl supernatant, was transferred to a transparent microplate having half-area and flat-bottom wells. The reaction results were analyzed as optical density using a iter plate reader at a wavelength of 415 nm.

A l sample (PSI0242, SEQ ID NO:1) and vehicle were included in each plate to define values for bited and fully inhibited reactions, respectively. These values were used to calculate the % inhibition of the complement hemolysis at any given sample concentration. The inhibitory potencies (lC 50-values) of tested C5 g compounds and polypeptide were defined by applying the same assay in the presence of a controlled concentration of human C5 added to C5 depleted serum. For highly potent inhibitors (low nanomolar to sub—nanomolar), a final C5 concentration of the reaction mixture was controlled at 0.1 nM, which was optionally established by using C5 depleted or deficient sera. The results are presented below in Table 6.

SEQ ID NO: Designation Potency (%) l IC 50 (nM) 1 PSI0242 100 | 0.47 13 PSI0378 83 0.58 22 PSI0400 - 4 23 PSI0410 107 l 0.49 Table 6. The inhibitory capacity of CS—binding compounds and ptide The results from the hemolysis assay show that the improved C5 g compounds PSI0378 (SEQ ID NO:13) and PSI0410 (SEQ ID NO:23) do not significantly differ from the reference compound PSI0242 (SEQ ID NO:1) in terms of function. The C5 binding polypeptide 0 (SEQ ID NO:22) is functional in the assay and since it does not comprise an n binding domain, the results cannot be directly compared to those of the reference compound.

Example 7 Binding to human albumin For assessment of the affinity of the C5 binding compounds for albumin, a human albumin ELISA was used, utilizing recombinant human albumin as coating (Novozymes) and commercially available antibodies from Affibody AB (primary) and tomation (detecting). A method standard prepared from PSI0242 (SEQ ID NO:1) and comprising a C5 g polypeptide and an albumin binding domain of ococcal protein G, was used for quantification of samples.

A 96-well late was coated with recombinant human albumin.

The plate was then washed with phosphate buffered saline containing 0.05 % Tween 20 (PBST) and blocked for 1-2 hours with 1 % casein in PBS. After a plate wash, the standard, method controls, control sample and test samples are added to the plate. After incubation for 2 hours, unbound material was removed by a wash. A goat anti-Affibody® IgG (Affibody AB, cat no. 201000010005) was added to the wells and the plate was incubated for 1.5 hours to allow binding to the bound C5 binding compounds. After a wash, rabbit anti-goat IgG HRP ytomation) was allowed to bind to the goat antibodies for 1 h. After a final wash, the amount of bound HRP was detected by addition of TMB substrate (3,3’,5,5’-tetramethy|benzidine), which was ted to a blue product by the enzyme. Addition of 1 M hydrochloric acid after 30 minutes stopped the reaction and the color of the well contents changed from blue to yellow. The absorbance at 450 nm was measured photometrically, using the ance at 650 nm as a reference wavelength.

The color intensity was proportional to the amount of PSI0242 (SEQ ID NO:1) and the sample concentrations were ined from the standard curve.

The C5 binding nds comprising a derivative of the albumin binding domain from streptococcal n G (ABD) were shown to be capable of binding to human albumin. Data is presented in Table 7. 2014/068259 SEQ ID NO: Designation % of total protein content 1 PSI0242 103 13 PSIO378 85 23 PSI0410 150 Table 7. Summary of results from ELISA The interpretation of the assay is that both the investigated C5 binding polypeptides with improved stability maintain their y to bind human serum Example 8 Three month stability test of C5 g Z variants and polypeptides The CS binding variants and polypeptides that showed an improved stability compared to PSI0242 in the 2 week stability test at 37 °C (Example 2) were subjected to a longer 3 month stability test at 37 °C. The setup of the stability test and the analysis by RPC was as described in Example 2. The evaluation of the stability was made by measuring the main peak of the chromatogram and calculating the corresponding percentage of the total protein content. The data from Example 2 is included in Table 8 below to make the interpretation easier.

Main peak Main peak (% of total protein) (% of total protein) P810334 73 16 13 PS|0378 89 59 14 PSI0379 88 58 PSI0381 87 46 16 PSI0383 91 59 23 PSI0410 72 16 24 PSI0403 77 35 PSI0404 88 46 Table 8. Stability of 05 binding polypeptides and nds after 3 months of incubation at 37 °C C5 g nds comprising the amino acid tutions ND to SE in positions 52-53 (SEQ ID NO:13, 14, and 16) compared to PSI0242 showed a higher proportion of protein in the al form after 3 months at 37 °C than PSI0242 (SEQ ID N021), after 2 weeks under the same conditions (see Table 1). The other tested compounds also y an increased stability compared to the PSI0242.

Example 9 Generation, stability study and binding assessment of scaffold-modified polypeptides with specificity for different targets Generation of scaffold-modified ptides with specificity for different targets: Polypeptide variants comprising the new scaffold described herein are generated by taking Z variant polypeptides with specificity for different targets, and performing site-directed mutagenesis at selected positions within the scaffold. The new molecules may, alternatively, be made by al synthesis of the entire le or by using other molecular biology methods, known to a person skilled in the art, to graft a binding motif of a Z variant polypeptide onto the new scaffold.

Comparative stability study of scaffold-modified polypeptides with specificity for different targets: For each new polypeptide created as described above, the stability is compared to the stability of the original polypeptide or another comparable polypeptide. The polypeptides are subjected to ent conditions, such as formulation in [25 mM NaP, 125 mM NaCl, pH 7.0] and incubation at 37 °C for 2 weeks as described in e 2 and/or for 3 months as described in Example 8. The stability is assessed by analyzing the appearance of new variants by performing SDS-PAGE and RPC analyses as described in Example 2.

Polypeptides with the introduced modifications in scaffold positions are expected to show improved stability in similar to the results presented in Example 2 and Example 12.

Binding assessment of scaffold-modified polypeptides: Polypeptides which have shown improved stability properties are further assessed in terms of preserved binding capacities to its target after introduction of alterations in the scaffold. Binding studies are performed on a biosensor instrument, or any other instrument known to the person d in the art and ing the interaction between two or more les. For example, the target molecule, or a fragment thereof, is immobilized on a sensor chip of the instrument, and the sample containing the polypeptide to be tested is passed over the chip.

Alternatively, the polypeptide to be tested is immobilized on a sensor chip of the ment, and a sample containing the predetermined target, or a fragment thereof, is passed over the chip. The binding affinity may be tested in an experiment in which samples of the polypeptide are captured on antibody-coated ELISA plates and biotinylated predetermined , or a fragment thereof, is added, followed by streptavidin conjugated HRP. TMB substrate is added and the absorbance at 450 nm is measured using a multi- well plate reader, such as Victor3 (Perkin Elmer). If a quantitative measure is desired, for example to ine the EC50 value (the half maximal effective tration) for the interaction, ELISA may also be used. The response of the polypeptide against a dilution series of the predetermined target, or a fragment thereof, is measured using ELISA as bed above. The results obtained by such experiments and E050 values may be calculated from the results using for example GraphPad Prism 5 and non—linear sion. If the polypeptide contains an albumin g domain, the effect on albumin binding will be assessed se, as described in Example 3 or as described in Example 7.

Polypeptides having the scaffold mutations described herein and, in addition, similar or improved binding capacities for its target, are considered to be better candidates for further development into e.g. rmaceutical products.

Example 10 Generation of scaffold-modified polypeptides with specificity for four different Eye—ts Polypeptide variants sing the new scaffold described herein were generated by taking 2 variant polypeptides with specificity for different targets, and performing site-directed mutagenesis at selected positions within the scaffold. Amino acid substitutions at scaffold ons in the polypeptide variants 202891 (SEQ ID NO:27), targeting the human epidermal growth factor receptor 2 (HER2); 215805 (SEQ ID NO:30), targeting the platelet- derived growth factor receptor beta (PDGF-RB); 210103 (SEQ ID NO:33), targeting the neonatal Fc receptor (FcRn); and 209782 (SEQ ID NO:36), targeting the carbonic anhydrase IX , are specified in Table 9.

D36R, 0370. 839E. N528. 053E 215805 ——m 31 217343 PDGF-R MR 0370. 839E, N528, D53E CAIx CAIX N528 Table 9. Original and inventive polypeptides produced and analyzed in terms of stability and function in the Examples described below All variants were cloned with an inal 6 x Histidine-tag (Hiss) and ed constructs d polypeptides in the format MGSSHHHHHHLQ- SUBSTITUTE SHEET (RULE 26) [Z#####]. Mutations were introduced in the plasmids of the inventive ptides using overlapping oligonucleotide primer pairs encoding the desired amino acid substitutions and by applying established molecular biology techniques. The correct plasmid ces were verified by DNA sequencing.

E coli n T7E2) cells (GeneBridge) were transformed with plasmids containing the gene fragments encoding the original and the inventive polypeptides. The cells were cultivated at 37 °C in TSB-YE medium supplemented with 50 ug/ml cin and protein expression was subsequently induced by addition of IPTG. Pelleted cells were disrupted using a FastPrep®-24 homogenizer (Nordic Biolabs) and cell debris was removed by centrifugation. Each supernatant containing the Z variant as a agged protein was purified by immobilized metal ion affinity chromatography (IMAC) using His GraviTrapT'VI columns (GE Healthcare) according to the manufacturers instructions. Purified Z variants were buffer exchanged to phosphate-buffered saline (PBS; 1.47 mM KHZPO4, 8.1 mM Na2HPO4, 137 mM NaCl, 2.68 mM KCI, pH 7.4) using PD-10 desalting columns (GE Healthcare). The correct identity of each polypeptide was verified by SDS— PAGE and S.

Example 11 Circular dichroism spectroscopy analysis of scaffold-modified polypeptides Circular dichroism (CD) analysis was carried out to determine the melting temperatures (Tm) and assess potential changes in the secondary structure of the inventive ptides as a result of the amino acid substitutions. ed Hiss—tagged Z variants were d to 0.5 mg/ml in PBS. For each diluted Z variant, a CD um at 250-195 nm was recorded at 20 °C.

A variable temperature ement (VTM) was performed to determine the Tm. In the VTM, the absorbance was measured at 221 nm while the temperature was raised from 20 to 90 °C, with a temperature slope of °C/min. After the VTM, a second CD spectrum at 5 nm was recorded at 20 °C. The CD measurements were performed on a Jasco J-810 spectropolarimeter (Jasco Scandinavia AB) using a cell with an optical path- length of 1 mm.

The Tm of each respective polypeptide as determined from the midpoint of the tion in the CD signal vs. temperature plot is shown in Table 10. All mutated polypeptides showed ved alphahelical ure and refolded ibly or nearly reversibly even after heating to 90 °C. A selected set of CD spectra are shown in Fig. 7.

SEQ ID NO Designation Target Tm (°C) Original vs inventive 27 202891 HER2 70 Original 28 217341 HER2 66 Inventive 29 217342 HER2 62 Inventive 215805 PDGF-RB 48 Original 31 217343 PDGF-RB 46 Inventive 32 217344 PDGF-RB 42 Inventive 33 210103 FcRn 48 Orioinal 34 217347 FcRn 50 Inventive 217348 FcRn 44 ive 36 209782 CAIX 43 Original 37 217351 CAIX 40 Inventive 38 217352 CAIX 45 Inventive 39 217355 CAIX 43 Inventive 40 217357 CAIX 47 Inventive 41 217359 CAIX 41 Inventive 42 217360 CAIX 46 Inventive Table 10. Melting temperatures for original and invenitve 2 variants determined by CD Example 12 Comparative ity study of scaffold-modified polypeptides with specificity for four different targets For each new polypeptide created as described in e 10, the stability was compared to the stability of the original polypeptide. The polypeptides, formulated in PBS pH 7.4, were diluted to 1 mg/ml and 200 pl aliquotes were incubated at 37 °C for 2 weeks. Samples collected prior to and after the stability test were analyzed by GE using 10% Bis-Tris NuPAGE gels (lnvitrogen) and by loading 5 pg n into each well. The resulting Coomassie blue stained gels are shown in Fig. 8. The stabilty was assessed by the ance of new ts after incubation at the elevated temperature and mutated variants were ed to respective original polypeptide.

All polypeptides with modifications introduced in scaffold positions as outlined in Table 9 showed improved stability compared to the respective original polypeptide. In samples of the original ptides a second band was visible on the gel just above the main band. A corresponding second band was not visible in the samples of the ive polypeptides with the substitution D53E and/or N528. This is in analogy with results presented in Examples 2 and 4. Thus, the stabilizing effect ed for the inventive scaffold mutations appears to be a general effect regardless of the target specificity of the Z variant or polypeptide comprising said Z variant.

Polypeptides with the substitutions D53E and/or N528, alone or combined with the substitutions D36R, D37Q and S39E, showed r profiles on the SDS—PAGE gel. The substition D53E alone or in combination with the substitutions D36R, D370 and 839E appeared to reduce the amount of the species with an alternative confirmation ed as a second band on the SDS—PAGE gel, but could not completely prevent the formation of this species.

Example 13 Binding assessment of scaffold-modified polypeptides A set of polypeptides showing ed stability properties in Example 12 were further assessed in terms of preserved binding capacities to their targets after introduction of alterations in the scaffold, as well as after having been subjected to the stability test, i.e. incubated at 37 °C for 2 weeks.

Comparative kinetic constants (kon and koff) and affinities (KD) were ined using a Biacore 2000 instrument. The target proteins human HER2-Fc (R&D Systems, cat. no. 1129-ER-050), human PDGF-RB (R&D s, cat. no. 385-PR-100/CF), human FcRn (Biorbyt, cat. no. orb 84388) and human CAIX (R&D s, cat. no. 2188-CA), tively, were immobilized on the carboxylated dextran layer surface of CM5 chips (GE Healthcare). The immobilization was performed using amine coupling chemistry according to the cturer’s protocol and using HBS—EP as running buffer. One flow cell surface on the chip was activated and deactivated for use as blank during analyte injections. The immobilization level of target protein on the respective surface was approximately 850 RU for HER2, 2200 RU for PDGF-RB, 750 for FcRn and 580 RU for CAIX.

HBS-EP (HER2, PDGF-RB, CAIX) or a pH 6.0 Na2HPO4/citric acid buffer (126 mM Na2HPO4, 37 mM citric acid) (FcRn) was used as running buffer and the flow rate was 30 ul/min in the binding experiments performed at 25 °C as further described below.

The Z variants 202891 (SEQ ID NO:27), 217341 (SEQ ID N028), and Z17342 (SEQ ID NO:29) targeting HER2 were diluted in running buffer to final concentrations of 3.33, 10, 30 and 90 nM and ed for 5 minutes, ed by 30 minutes of dissociation in running . Regeneration by four pulses alternating between 10 mM HCI and 10 mM NaOH followed by 5 min equilibration in running buffer was applied after each analyte injection.

The Z variants Z15805 (SEQ ID NO:30), Z17343 (SEQ ID NO:31), and 217344 (SEQ ID NO:32) targeting PDGF-RB were diluted in g buffer to final concentrations of 6.67, 20, 60 and 180 nM and injected for 5 minutes, followed by 20 minutes ofdissociation in running buffer. Regeneration by three pulses of 10 mM NaOH ed by 5 min equilibration in running buffer was applied after each analyte injection.

The Z variants Z10103 (SEQ ID NO:33), Z17347 (SEQ ID NO:34), and Z17348 (SEQ ID NO:35) targeting FcRn were diluted in running buffer to final concentrations of 3.33, 10 and 30 nM and injected for 3 minutes, followed by s ofdissociation in running buffer. Regeneration by three pulses of 2014/068259 HBS-EP followed by 10 min equilibration in running buffer was applied after each analyte injection.

The Z variants 209782 (SEQ ID NO:36), 217351 (SEQ ID NO:37), 217355 (SEQ ID NO:39), and 217359 (SEQ ID NO:41) targeting CAIX were diluted in g buffer to final concentrations of 30, 90 and 270 nM and ed for 5 minutes, followed by 15 minutes of dissociation in running buffer. ration by three pulses of 10 mM glycin-HCI pH 3.0 followed by min equilibration in running buffer was applied after each analyte injection. c constants were calculated from the sensorgrams using the Langmuir 1 :1 model (HER2, FcRn, CAIX) or the 1:1 binding with mass transfer model (PDGF-RB) of the luation software 4.1 (GE Healthcare).

Curves of the blank surface were subtracted from the curves of the ligand surfaces and the data from the buffer cycles were subtracted from the data of the test-sample cycles to correct for any drift in signal.

The comparative kinetic constants for 2 variants binding to its target molecule are shown in Table 11 and sensorgrams for a subset of the analyzed interactions are shown in Fig. 9. The data show that the affinity is only marginally effected by the substitutions ND to SE in position 52-53 and for a couple of variants, 217341 (SEQ ID N028) and 217343 (SEQ ID , the affinity is even slighty improved. A combination of the substitutions ND to SE in position 52-53 with the substitutions D36R, D37Q and S39E, such as in 217342 (SEQ ID NO:29), 217344 (SEQ ID NO:32) and 217348 (SEQ ID NO:35) had a more ve effect on the affinity primarily due to faster dissociation rates, but yet, functional binders were obtained with KD in the range 10'9M. The assessed variants also had preserved binding capabilities after 2 weeks incubation at 37 °C.

HER2 bindin . Z variants Original VS .1 KDinv/ KDlZwll ——I-——_——_ “___-E.- 37 il-31 PDGF-Rt bindin Z variants mum..

KD(2w) Original vs KDlnvl “I‘m—“- 1-47 1-77x10' 3-7x10'm 1-90 _—l-—__—__ _562x10 FcRn bindin - Z ts Original vs K / me, Test sample Dinv..

| . I nventlve Knofig ...

K0 0 210103 0 1.60x10 0' 2.9x10‘ _- 210103 (2w) 3.15x1o 5.75 x10'3 1.8x10‘ 34 217347 (0) Inventive 1.18x1o'5 7.99 x10'3 6.7x10‘ _— 217347 (2w 2.27x1o 8.79x10‘ 3.9x10' _z1734810) 1.82x10 1.00x10' 5.5x10' _- 217348 2w Inventive 1.28x10 8.09 x10‘ 6.3x10' CAIXbindin . Z variants SEQ Original vs- - KD(2w) KDlnvI 36 209782 (0) al 2.08x10 1.46x10‘ 7.0x10' _— _209782 2w 1.40x1o 1.38x10' 9.9x10‘ IE.— z_17351 0 1.51x10 2.63x10' 1.8x10‘ _- 1 2w 1.91x1o 2.86x10‘ 1.5x10' _z17355 o 1.57x10 1.23x10' 7.9x10' _— _217355 2w 1.16x10 0' 1.1x10' 1,07 _z17359(0) 168x10 2-15x10' ___ _z17359 2w 1.78x10 2.33x10' 1.3x10' 1.02 Table 11 . Comparative c analysis of original and inventive polypeptides SUBSTITUTE SHEET (RULE 26) * The KD values should not be regarded as absolute, as these were determined for comparative purposes and only ed a limited number of sample concentrations.

** Relative KD comparing the K0 of respective inventive polypeptide With the K0 of its original polypeptide (set to 1.0) either prior to (0) or after the stability test (2W) described in Example 12.

*** Relative KD ing the K0 from (2W) with KD from (0) for each polypeptide pair identical in sequence.

ED LIST OF EMBODIMENTS 1. Polypeptide comprising an amino acid sequence selected from: i) EX2X3X4AX6X7EIX10 X11LPNLX16X17X1BQX20 X21AFIX25X26LX28X29X30 PX32QSX35X35LLX39E 5X45X4yQ, wherein each of X2, X3, X4, X6, X7, X10, X11, X17, X18, X20, X21, X25 and X28 independently corresponds to any amino acid residue; and wherein, independently of each other, X15 is selected from N and T; X25 is selected from K and S; X29X30PX32 is selected from DDPS and RQPE; X35 is selected from A and S; X35 is ed from E and N; X39 is selected from A, C and S; X45 is selected from E, N and S; X46 is selected from D, E and 8, provided that X45 is not D when X45 is N; X47 is selected from A and S; and ii) an amino acid sequence which has at least 91 % identity to the sequence d in i), provided that X45 is not D when X45 is N. 2. Polypeptide according to item 1, wherein X16 is T. 3. ptide according to item 1 or 2, wherein X26 is K. 4. Polypeptide according to any preceding item, wherein X29X30PX32 is DDPS.

. Polypeptide according to item 1-3, wherein X29X30PX32 is RQPE. 6. Polypeptide according to any preceding item, n X35 is S. 7. Polypeptide according to any preceding item, wherein X36 is E. 8. Polypeptide according to any preceding item, wherein X39 is S. 9. Polypeptide according to any preceding item, wherein X45 is selected from E and S. 10. Polypeptide according to item 9, wherein X45 is E. 11. Polypeptide ing to item 9, wherein X45 is S. 12. Polypeptide according to any ing item, wherein X45 is selected from E and S. 13. Polypeptide according to item 12, n X45 is E. 14. Polypeptide according to item 12, wherein X45 is S.

. Polypeptide according to item 12, wherein X46 is D. 16. Polypeptide according to any preceding item, provided that X45 is not D or E when X45 is N. 17. Polypeptide according to any preceding item, wherein X45X45 is selected from EE, ES, SE and SS. 18. Polypeptide according to item 17, wherein X45X46 is selected from ES and SE. 19. Polypeptide according to item 18, wherein X45X46 is ES.

. Polypeptide according to item 18, wherein X45X45 is SE. 21. Polypeptide according to item 18, wherein X45X45 is SD. 22. Polypeptide according to any ing item, wherein X47 is S. 23. Polypeptide according to any one of items 1-22, comprising additional amino acid residues. 24. ptide according to item 23, comprising additional amino acid residues at the C-terminus of said polypeptide. 25. Polypeptide according to item 24, wherein the additional amino acid residues at the C-terminus of said polypeptide comprise AP. 26. Polypeptide ing to item 23, comprising additional amino acid residues at the N-terminus of said polypeptide. 27. Polypeptide according to item 26, wherein the additional amino acid residues at the N—terminus of said polypeptide comprise AEAKYAK. 28. Polypeptide according to any one of items 23-27, wherein said additional amino acid residues are added for the purpose of binding, production, purification, ization, ng or detection of the polypeptide. 29. Polypeptide according to any one of items 23-28, n said additional amino acid residues constitute one or more polypeptide domain(s).

. Polypeptide ing to item 29, wherein said one or more polypeptide domain(s) has a function selected from the group of a binding function, an enzymatic function, a metal ion chelating function and a fluorescent function, or mixtures thereof. 31. Polypeptide according to any one of items 1—28, which comprises an amino acid sequence selected from: YAK EX2X3X4AX5X7EIX10 LX16X17X18QX20 X21AFIX25X26LX28X29X30 PX3ZQSX35X36LLX39E AKKLX45X45X47Q AP; and FNK 4AX6X7EIX10 X11LPNLX15X17X1BQX20 X21AFIX25X26LX28X29X30 PX3zQSX35X36LLX39E AKKLX45X45X4yQ AP, wherein each Xy is as defined in any one of items 1-22. 32. Polypeptide according to item 31, which comprises an amino acid sequence selected from: ADNNFNK EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20 X21AFIX25X26LX28X29X30 X35X36LLX39E AKKLX45X45X4yQ APK; ADNKFNK EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20 X21AFIX25X26LX28X29X30 PX3ZQSX35X36LLX39E AKKLX45X46X4yQ APK; VDNKFNK EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20 X21AFIX25X26LX28X29X30 PX3zQSX35X36LLX39E AKKLX45X46X4yQ APK; VDAKYAK EX2X3X4AX6X7EIX10 X11LPNLX16X17X1BQX20 X21AFIX25X26LX28X29X30 PX3zQSX35X35LLX39E AKKLX45X45X4yQ APK; and AEAKYAK EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20 X25X26LX28X29X30 PX3208X35X36LLX39E AKKLX45X45X4yQ APK; wherein each Xy is as d in any one of items 1—22. 33. Polypeptide ing to any one of items 1-32 having an ty for a predetermined target, wherein said target is optionally selected from the group consisting of ABD, HER2, TNFa, EGFR, |GF1R, lgG, , HER3, C5, FcRn, CAIX, amyloid [3, CD4, |L8, |L6 and insulin. 34. Fusion polypeptide comprising a polypeptide according to any one of items 1-33 as a moiety. . ptide or fusion polypeptide according to any one of items 1- 34, further comprising a label. 36. Polypeptide or fusion polypeptide according to any one of items 1- , further comprising a therapeutic agent. 37. Use of a polypeptide or fusion polypeptide according to any one of items 1-36 as a ion reagent, capture reagent or separation t. 38. Polypeptide or fusion polypeptide according to any one of items 1- 36 for use in y. 39. Polypeptide or fusion polypeptide according to any one of items 1- 36 for use as a stic agent. 40. Polynucleotide encoding a polypeptide or fusion ptide according to any one of items 1-34. 41. Population of polypeptide variants based on a common scaffold, each ptide in the population comprising an amino acid sequence selected from: i) EX2X5X4AX5X7EIX10 X11LPNLX15X17X1gQX25 X21AFIX25X25LX25X29X50 PX32QSX35X35LLX39E AKKLX45X45X47Q, wherein each of X2, X5, X4, X5, X7, X10, X11, X17, X15, X20, X21, X25 and X25 independently corresponds to any amino acid residue; and wherein, independently of each other, X15 is selected from N and T; X25 is selected from K and S; X29X50PX32 is selected from DDPS and RQPE; X35 is selected from A and S; X35 is selected from E and N; X55 is selected from A, C and S; X45 is ed from E, N and S; X45 is selected from D, E and 8, provided that X45 is not D when X45 is N; X47 is selected from A and S; and ii) an amino acid sequence which has at least 91 % identity to the sequence defined in i), provided that X45 is not D when X45 is N. 42. Population according to item 41, which comprises at least 1 X 104 unique polypeptide molecules. 43. Population according to item 42, which comprises at least 1 x 106 unique polypeptide molecules. 44. Population according to item 43, which comprises at least 1 X 108 unique polypeptide molecules. 45. Population ing to item 44, which comprises at least 1 x 1010 unique polypeptide molecules. 46. Population according to item 45, which comprises at least 1 x 1012 unique polypeptide les. 47. Population according to item 46, which comprises at least 1 x 1014 unique polypeptide molecules. 48. Population of polynucleotides, characterized in that each member thereof encodes a member of a population of polypeptides ing to any one of items 41 -47. 49. Combination of a ptide population according to any one of items 41 -47 with a polynucleotide population ing to item 48, wherein each member of said population of polypeptides is physically or spatially ated with the polynucleotide encoding that member via means for genotype-phenotype ng. 50. Combination according to item 49, wherein said means for genotype-phenotype coupling comprises a phage display system. 51. Combination according to item 49, wherein said means for genotype—phenotype coupling comprises a cell surface selection display system. 52. Combination according to item 51, wherein said cell surface display system comprises prokaryotic cells. 53. Combination according to item 52, wherein said prokaryotic cells are Gram-positive cells. 54. Combination according to item 51, wherein said cell surface display system comprises eukaryotic cells. 55. Combination according to item 54, wherein said eukaryotic cells are yeast cells. 56. Combination according to item 49, wherein said means for genotype-phenotype coupling comprises a cell free y system. 2014/068259 57. Combination according to item 56, wherein said cell free display system comprises a ribosome display system. 58. Combination according to item 56, n said cell free y system comprises an in vitro compartmentalization display system. 59. Combination according to item 56, wherein said cell free display system comprises a system for 0/3 display. 60. Combination according to item 56, wherein cell free display system ses a microbead display system. 61. Combination according to item 49, wherein said means for genotype-phenotype coupling comprises a non-display system. 62. Combination according to item 61, wherein said non-display system is protein-fragment complementation assay. 63. Method for selecting a desired polypeptide having an affinity for a predetermined target from a population of polypeptides, comprising the steps: (a) providing a population of polypeptides according to any one of items 41 -47; (b) bringing the population of polypeptides into contact with the predetermined target under conditions that enable ic interaction between the target and at least one desired polypeptide having an ty for the ; and (c) selecting, on the basis of said specific interaction, the at least one desired polypeptide from the remaining population of polypeptides. 64. Method according to item 63, wherein step (a) comprises the preparatory steps of providing a population of cleotides according to item 48 and expressing said population of polynucleotides to yield said population of polypeptides. 65. Method according to item 64, wherein each member of said population of polypeptides is physically or spatially associated with the polynucleotide ng that member via means for genotype-phenotype coupling. 66. Method ing to item 65, wherein said means for genotype- phenotype coupling is as defined in any one of items 50-62. 67. Method for isolating a polynucleotide encoding a desired polypeptide having an affinity for a predetermined target, comprising the steps: - selecting said desired polypeptide and the polynucleotide encoding it from a population of polypeptides using the method according to item 63; and - isolating the thus separated polynucleotide encoding the desired polypeptide. 68. Method for identifying a desired polypeptide having an affinity for a predetermined target, sing the steps: - isolating a polynucleotide encoding said desired polypeptide using the method according to item 67; and - sequencing the polynucleotide to establish by deduction the amino acid ce of said desired polypeptide. 69. Method for selecting and fying a desired polypeptide having an affinity for a predetermined target from a population of polypeptides, comprising the steps: (a) synthesizing each member of a population of polypeptides according to any one of items 41 -47 on a separate carrier or bead; (b) selecting or ing the carriers or beads based on the interaction of the polypeptide with the predetermined target; and (c) fying the polypeptide by protein characterization methodology. 70. Method according to item 69, wherein the n characterization methodology used in step (c) is mass spectrometric analysis. 71. Method for production of a desired polypeptide having an ty for a predetermined target, comprising the steps: - ing and identifying a desired polypeptide using the method according to item 68 or selecting and identifying a desired polypeptide using the method according to any one of items 69 and 70; and - producing said desired polypeptide. 72. Method according to item 71, n said production is carried out using chemical synthesis of the desired polypeptide de novo. 73. Method according to item 71, wherein said production is carried out using recombinant expression of a polynucleotide ng the desired polypeptide. 74. Method for production of a d polypeptide having an affinity for a predetermined target, comprising the steps: (a1) isolating a polynucleotide encoding said desired polypeptide using the method according to item 68; or (a2) backtranslating a polypeptide fied using the selection and identification method according to any one of items 69 and 70; and (b), following either (a1) or (a2), expressing the thus isolated polynucleotide to produce said desired polypeptide.

Claims (16)

1. Polypeptide sing an amino acid ce selected from: 5 i) EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20 X21AFIX25X26LX28X29X30 PX32QSX35X36LLX39E AKKLX45X46X47Q, wherein each of X2, X3, X4, X6, X7, X10, X11, X17, X18, X20, X21, X25 and X28 independently corresponds to any amino acid residue; and wherein, independently of each other, X16 is selected from N and T; X26 is selected from K and S; X29X30PX32 is selected from DDPS and RQPE; 15 X35 is selected from A and S; X36 is selected from E and N; X39 is selected from A, C and S; X45 is selected from E and S; X46 is selected from D, E and S; 20 X47 is ed from A and S; and ii) an amino acid sequence which has at least 91 % identity to the sequence defined in i), provided that X46 is not D or E when X45 is N. 25

2. Polypeptide according to claim 1, wherein X45 is S.

3. Polypeptide according to claim 1 or 2, wherein X45X46 is selected from ES and SE. 30

4. Polypeptide according to claim 3, wherein X45X46 is SE.

5. ptide according to any one of claims 1-4, which comprises an amino acid sequence selected from: YAK EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20 X21AFIX25X26LX28X29X30 5 PX32QSX35X36LLX39E AKKLX45X46X47Q AP; and FNK EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20 X21AFIX25X26LX28X29X30 PX32QSX35X36LLX39E AKKLX45X46X47Q AP, 10 wherein each Xy is as defined in any one of claims 1-4, wherein y denotes the amino acid on of residue X within the polypeptide sequence d by

6. Fusion polypeptide comprising the polypeptide according to any one of 15 claims 1-5 as a moiety.

7. Polynucleotide encoding the polypeptide or fusion polypeptide according to any one of claims 1-6. 20

8. Population of polypeptide variants based on a common scaffold, each polypeptide in the tion comprising an amino acid ce selected from: i) EX2X3X4AX6X7EIX10 X11LPNLX16X17X18QX20 25 X21AFIX25X26LX28X29X30 PX32QSX35X36LLX39E AKKLX45X46X47Q, wherein each of X2, X3, X4, X6, X7, X10, X11, X17, X18, X20, X21, X25 and X28 independently corresponds to any amino acid residue; and 30 wherein, independently of each other, X16 is selected from N and T; X26 is selected from K and S; X29X30PX32 is selected from DDPS and RQPE; X35 is selected from A and S; X36 is selected from E and N; X39 is selected from A, C and S; 5 X45 is ed from E and S; X46 is selected from D, E and S; X47 is selected from A and S; and ii) an amino acid sequence which has at least 91 % identity to the sequence 10 defined in i), provided that X46 is not D or E when X45 is N.

9. tion ing to claim 8, which comprises at least 1 x 104 unique polypeptide molecules. 15

10. Population of polynucleotides, characterized in that each member thereof encodes a member of the population of polypeptides according to any one of claims 8-9.

11. Combination of the polypeptide population according to any one of claims 20 8-9 with the polynucleotide population according to claim 10, wherein each member of said population of polypeptides is physically or spatially associated with the polynucleotide encoding that member via means for genotype-phenotype coupling. 25

12. Combination according to claim 11, wherein said means for genotypephenotype coupling comprises a phage display .

13. Method for selecting a desired polypeptide having an affinity for a ermined target from a population of polypeptides, comprising the steps: 30 (a) providing the population of ptides according to any one of claims 8-9; (b) bringing the population of polypeptides into contact with the predetermined target under conditions that enable specific interaction n the target and at least one desired polypeptide having an affinity for the target; and 5 (c) selecting, on the basis of said specific interaction, the at least one desired polypeptide from the remaining population of polypeptides.

14. Method for isolating a polynucleotide encoding a desired polypeptide having an ty for a predetermined target, comprising the steps: 10 - selecting said desired polypeptide and the cleotide encoding it from a population of polypeptides using the method according to claim 13; - isolating the thus separated polynucleotide encoding the desired ptide.

15. Method for fying a desired polypeptide having an affinity for a predetermined target, comprising the steps: - isolating a polynucleotide encoding said desired polypeptide using the method according to claim 14; and 20 - sequencing the polynucleotide to establish by deduction the amino acid sequence of said desired polypeptide.

16. Method for selecting and identifying a desired polypeptide having an ty for a predetermined target from a population of polypeptides, 25 comprising the steps: (a) synthesizing each member of the population of ptides according to any one of claims 8-9 on a separate carrier or bead; (b) selecting or enriching the carriers or beads based on the interaction of the polypeptide with the predetermined target; and 30 (c) identifying the ptide by protein characterization methodology.